Product Information
Catalog Number:
DH1199
Lot Number:
DH1199-100515
Quantity:
1 vial (4 x 106) frozen cells
Freeze Medium:
Sigma Freezing Medium (C-6164)
Host cell:
HEK293T
Transfection:
Full-length Human BDKRB2 cDNA (GenBank Accession Number NM_000623) with FLAG-tag sequence at the N-terminus
Recommended Storage:
Liquid nitrogen upon receiving
Propagation Medium: DMEM, 10% FBS
Stability:
Stable for 1-2 days after thawing
Data Sheet
Background: Bradykinin receptor B2 is a G protein-coupled receptor for bradykinin. B2 receptor agonists may have important clinical value in the treatment and prevention of various cardiovascular disorders such as hypertension, ischemic heart disease, left ventricular hypertrophy, ventricular remodeling and congestive heart failure, as well as diabetic disorders by mimicking the reported beneficial effects of bradykinin. Blocking bradykinin B2 receptors after experimental cerebral ischemia reduces brain edema, infarct volume and neuronal necrosis, and improves neurological outcome. Thus, B2 antagonists may be a promising new class of compounds for clinical use after the onset of cerebral ischemia.
Application: Functional assays
Figure 1. Dose-dependent stimulation of intracellular cAMP level upon treatment with ligand, measured with MultiscreenTM TR-FRET cAMP 1.0 No Wash Assay Kit (Multispan MSCM01).
References:
Hess et al. (1992) Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. Biochem Biophys Res Commun 184:260-268.
Heitsch (2003) The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease. Expert Opin Investig Drugs 12:759-770.
Sobey (2003) Bradykinin B2 receptor antagonism: a new direction for acute stroke therapy? Br J Pharmacol 139:1369-1371.